{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 400125842
| IUPAC_name = 7-methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one
| image = Ensaculin.png
| width = 240

<!--Clinical data-->
| tradename =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| elimination_half-life = 13.7 hours

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 155773-59-4
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 208923
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1963107
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 181019
|  smiles = O=C/4Oc3cc(OC)c(OCCCN2CCN(c1ccccc1OC)CC2)cc3\C(=C\4C)C
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C26H32N2O5/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3/h5-6,8-9,16-17H,7,10-15H2,1-4H3
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = FQELZLMTAPJJOL-UHFFFAOYSA-N
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 869PGR00AT

<!--Chemical data-->
| C=26 | H=32 | N=2 | O=5 
| molecular_weight = 452.543
}}

'''Ensaculin''' ('''KA-672''') is a drug from the [[coumarin]] family, which has been researched as a potential treatment for [[dementia]]. It acts on a number of receptor systems, being both a weak [[NMDA antagonist]] and a [[5HT1A receptor|5HT<sub>1A</sub>]] agonist.<ref>{{cite journal | last1 = Lishko | first1 = PV | last2 = Maximyuk | first2 = OP | last3 = Chatterjee | first3 = SS | last4 = Nöldner | first4 = M | last5 = Krishtal | first5 = OA | title = The putative cognitive enhancer KA-672.HCl is an uncompetitive voltage-dependent NMDA receptor antagonist | journal = NeuroReport | volume = 9 | issue = 18 | pages = 4193–7 | year = 1998 | pmid = 9926872 | doi = 10.1097/00001756-199812210-00035 }}</ref><ref>{{cite journal | last1 = Winter | first1 = JC | last2 = Helsley | first2 = SE | last3 = Rabin | first3 = RA | title = The discriminative stimulus effects of KA 672, a putative cognitive enhancer: evidence for a 5-HT1A component | journal = Pharmacology, Biochemistry, and Behavior | volume = 60 | issue = 3 | pages = 703–7 | year = 1998 | pmid = 9678654 | doi=10.1016/S0091-3057(98)00043-4}}</ref> Animal studies have shown promising [[nootropic]] effects,<ref>{{cite journal | last1 = Hoerr | first1 = R | last2 = Noeldner | first2 = M | title = Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment | journal = CNS Drug Reviews | volume = 8 | issue = 2 | pages = 143–58 | year = 2002 | pmid = 12177685 | doi=10.1111/j.1527-3458.2002.tb00220.x}}</ref><ref>{{cite journal | last1 = Knauber | first1 = J | last2 = Müller | first2 = WE | title = Anseculin improves passive avoidance learning of aged mice | journal = Pharmacological research : the official journal of the Italian Pharmacological Society | volume = 47 | issue = 3 | pages = 225–33 | year = 2003 | pmid = 12591018 | doi=10.1016/S1043-6618(02)00311-0}}</ref> although efficacy in humans has yet to be proven. It was well tolerated in human trials, with the main side effect being orthostatic [[hypotension]] (low blood pressure).<ref>{{cite journal | last1 = Sourgens | first1 = H | last2 = Hoerr | first2 = R | last3 = Biber | first3 = A | last4 = Steinbrede | first4 = H | last5 = Derendorf | first5 = H | title = KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers | journal = Journal of clinical pharmacology | volume = 38 | issue = 4 | pages = 373–81 | year = 1998 | pmid = 9590466 | doi=10.1002/j.1552-4604.1998.tb04438.x}}</ref>

== References ==
{{Reflist|2}}

{{Piperazines}}
{{Nootropics}}
{{Anti-dementia drugs}}
{{coumarin}}

[[Category:Nootropics]]
[[Category:Piperazines]]
[[Category:Coumarin drugs]]
[[Category:Phenol ethers]]


{{nervous-system-drug-stub}}